-
-
-
-
-
-
-
Visionary Copper plans 20,000-metre Phase 2 drill program in Newfoundland
-
-
-
-
-
-
-
Biohaven stock tumbles after pausing trial enrollment
-
-
-
-
-
-
-
FDA grants priority review to Genentech's Enspryng for rare disease MOGAD
-
-
-
-
-
-
-
Propanc Biopharma plans Phase 1b cancer drug trial for February 2027
-
-
-
-
-
-
-
Opus Genetics reports early positive data from gene therapy eye trial
-
-
-
-
-
-
-
Satellos drug candidate SAT-3247 receives WHO nonproprietary name
-
-
-
-
-
-
-
Pyxis Oncology to webcast MICVO cancer drug data on Sept. 9
-
76,957 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.

